Evaluating the Effectiveness and Value of Novel Nonhormonal Treatments in the Management of Menopause-Related Vasomotor Symptoms

This activity was originally broadcast in conjunction with AMCP 2025.

Program Description

Menopause is a life-changing transition for women and can often lead to challenges in sleep patterns, daily routines, and quality of life. Vasomotor symptoms (VMS), such as hot flashes and night sweats, are common, with estimates suggesting 60% to 85% of women experience them. This session will focus on the impact of VMS on health-related quality of life, with real-world data underscoring the burden of these symptoms and disparities in access to effective treatment. While hormone therapy remains a viable option for many women, its use is not without risks and is not recommended for all women, which underscores the importance of individualized treatment approaches. Expert faculty will discuss managed care considerations for evidence-based, targeted treatment of VMS, with a focus on the efficacy and safety profiles of novel nonhormonal therapies, such as neurokinin 3 receptor (NK3R) antagonists, that target the underlying mechanisms of VMS. The session will prepare managed care professionals with strategies for applying evidence to ensure access to the most appropriate and effective therapies, including eligibility/exclusion criteria, shared decision-making, and the value of nonhormonal therapies for VMS.

Target audience: Managed care pharmacists

Type of activity: Application
Release date: April 10, 2025
Expiration date: April 10, 2026

Time to complete activity: 1.5 hours

Learner level: Foundational
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explain the health burden associated with vasomotor symptoms (VMS) in menopause and the risk/benefit profile of hormonal therapy.
• Examine the efficacy and safety data for novel nonhormonal therapies in the treatment of bothersome menopause symptoms, including VMS and sleep disturbances.
• Explore the health care resource utilization and economic burden associated with VMS and the need for a personalized treatment approach to improve menopause-related quality of life.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-25-093-H01-P. The activity is available for CE credit through April 10, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Faculty

Amanda Williams, PharmD, RPh, has the following relevant financial relationship with a commercial interest to disclose: Employee of PBM: Gainwell Technologies.

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Lisa S. Miller, PharmD, MA

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Dipti Desai, PharmD, MBA, CHCP; Aleksandra Thomas; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green.

 
At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms